EMEA-000997-PIP01-10-M05
Key facts
| Invented name |
Uptravi
|
| Active substance |
Selexipag
|
| Therapeutic area |
Other
|
| Decision number |
P/0328/2021
|
| PIP number |
EMEA-000997-PIP01-10-M05
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of pulmonary arterial hypertension
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Janssen-Cilag International NV
E-mail: ClinicalTrialsEU@its.jnj.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|